Table 6. Univariate analysis of progression-free survival and overall survival in patients with the EGFR mutation.

Parameter	No. of patients	Progression-free survival		Overall survival
		Mean survival time(months ±SE)	P value	Mean survival time(months ±SE)	P value
Age
<64	57	13.27±2.04	0.504	30.45±1.65	0.503
≥64	34	14.77±1.61		27.42±1.93
Sex
Male	34	13.90±1.90	0.869	27.68±1.85	0.494
Female	57	14.05±1.64		30.22±1.66
Smoker
+	48	11.57±1.19	0.147	27.79±1.52	0.344
-	43	16.34±2.09		30.95±2.02
ECOG performance status
0/1	73	14.98±1.51	0.215	30.57±1.49	0.236
2/3/4	18	9.58±1.35		25.20±3.03
Serum CEA level
Normal(≤5)	31	18.72±2.65	0.049	33.31±2.30	0.078
High(>5)	60	11.75±1.18		27.07±1.38
Serum LDH level
High	14	6.71±0.91	0.000	21.87±2.81	0.002
Normal	77	16.09±1.54		31.07±1.48
TLGT
<104.65	57	14.91±1.57	0.215	30.87±1.66	0.506
≥104.65	34	12.98±2.09		26.77±1.95
TLGWBR
<259.85	59	16.66±1.57	0.000	31.83±1.61	0.018
≥259.85	32	9.84±1.85		24.62±1.87

Abbreviations: ECOG: Eastern Cooperative Oncology Group; TLG_T: primary tumor total lesion glycolysis (TLG); TLG_WBR: whole-body total TLG determined using the Response Evaluation Criteria In Solid Tumors 1.1 criteria.